Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Key House committee advances nationwide voter ID bill,...
FDA refuses to review Moderna’s mRNA flu vaccine...
Trump, Netanyahu to meet at White House in...
Vance warns Iran that ‘another option on the...
Meta, Google face massive liability as ‘addicted kids’...
Trump to host ‘Clean Beautiful Coal’ event, calls...
Russia agrees to abide by expired New START...
Israel joins Board of Peace ahead of Netanyahu-Trump...
Bondi confirms DOJ has received criminal referral alleging...
Schumer, Dems choose partial shutdown as negotiations hit...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

previous post
Putin’s ‘Fog of War’ missile confuses experts, but that’s his plan
next post
Stop funding the woke and the stupid

You may also like

Graham demands Democrats explain ‘refuse illegal orders’ message...

November 20, 2025

Billion-dollar Mexican cartel ops disrupted by Trump’s border...

January 30, 2025

Trump calls White House talks ‘very good, early...

August 19, 2025

Supreme Court to hear case on LGBTQ-themed storybooks...

April 22, 2025

PETA, animal rights groups praise Trump admin for...

April 14, 2025

HOLLYWOOD ELITES FOR HARRIS: Celebs sign on for...

October 14, 2024

President Trump reveals what he told Zelenskyy during...

May 1, 2025

Trump energy plan will avoid Europe’s energy disaster

January 8, 2025

Former FBI and CIA chief urges senators to...

December 28, 2024

Federal judge blocks Trump administration from enforcing mail-in...

January 11, 2026

Recent Posts

  • Key House committee advances nationwide voter ID bill, setting up 2026 election fight
  • FDA refuses to review Moderna’s mRNA flu vaccine application
  • Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan
  • Vance warns Iran that ‘another option on the table’ if nuclear deal not reached
  • Meta, Google face massive liability as ‘addicted kids’ trial continues in LA

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (973)
    • Investing (4,091)
    • Politics (4,927)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 Sightful Invest. All Rights Reserved.